Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies - PubMed (original) (raw)
. 2007 Dec 12:1184:284-94.
doi: 10.1016/j.brainres.2007.09.048. Epub 2007 Oct 25.
Eizo Iseki, Ryoko Yamamoto, Michiko Minegishi, Hiroaki Hino, Koshiro Fujisawa, Takashi Togo, Omi Katsuse, Hirotake Uchikado, Yoshiko Furukawa, Kenji Kosaka, Heii Arai
Affiliations
- PMID: 17963732
- DOI: 10.1016/j.brainres.2007.09.048
Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies
Shinji Higashi et al. Brain Res. 2007.
Abstract
TAR-DNA-binding protein 43 (TDP-43) has been identified as a major component protein of ubiquitin-positive inclusions in brains from patients with frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U) and amyotrophic lateral sclerosis. To obtain the precise prevalence of TDP-43 pathology in neurodegenerative disorders, we examined brains from patients with tauopathies and synucleinopathies as well as FTLD-U using immunohistochemical analysis. Consequently, TDP-43-positive inclusions within neurons and oligodendroglia were found in brains from patients with Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) in addition to FTLD-U, but not with Parkinson's disease, Pick's disease, progressive supranuclear palsy, corticobasal degeneration or FTDP-17. The amygdala and hippocampus that were vulnerable to tau or alpha-synuclein pathology demonstrated more severe TDP-43 pathology in AD and DLB cases than in FTLD-U cases. In contrast, in the frontal cortex and basal ganglia that were vulnerable to TDP-43 pathology in FTLD-U, TDP-43 pathology was not observed in AD and DLB cases. Thus, the neuroanatomical distribution of TDP-43 pathology in AD and DLB cases was obviously different from that in FTLD-U cases. Furthermore, a subset of TDP-43-positive inclusions co-existed with neurofibrillary tangles (NFTs) or Lewy bodies (LBs) in the same neurons. Upon double-immunofluorescent labeling analysis, TDP-43 was hardly superimposed with tau, while TDP-43 was partially superimposed with alpha-synuclein, suggesting that neither NFTs nor LBs themselves show TDP-43 immunoreactivity and that TDP-43 pathology found in this study may be related in some way to AD and LB pathology. This study will provide a more in-depth understanding of the various pathogenic pathways leading to neurodegenerative disorders.
Similar articles
- Phosphorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies.
Arai T, Mackenzie IR, Hasegawa M, Nonoka T, Niizato K, Tsuchiya K, Iritani S, Onaya M, Akiyama H. Arai T, et al. Acta Neuropathol. 2009 Feb;117(2):125-36. doi: 10.1007/s00401-008-0480-1. Epub 2009 Jan 13. Acta Neuropathol. 2009. PMID: 19139911 - Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases.
Nakashima-Yasuda H, Uryu K, Robinson J, Xie SX, Hurtig H, Duda JE, Arnold SE, Siderowf A, Grossman M, Leverenz JB, Woltjer R, Lopez OL, Hamilton R, Tsuang DW, Galasko D, Masliah E, Kaye J, Clark CM, Montine TJ, Lee VM, Trojanowski JQ. Nakashima-Yasuda H, et al. Acta Neuropathol. 2007 Sep;114(3):221-9. doi: 10.1007/s00401-007-0261-2. Epub 2007 Jul 25. Acta Neuropathol. 2007. PMID: 17653732 - Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated.
Robinson JL, Lee EB, Xie SX, Rennert L, Suh E, Bredenberg C, Caswell C, Van Deerlin VM, Yan N, Yousef A, Hurtig HI, Siderowf A, Grossman M, McMillan CT, Miller B, Duda JE, Irwin DJ, Wolk D, Elman L, McCluskey L, Chen-Plotkin A, Weintraub D, Arnold SE, Brettschneider J, Lee VM, Trojanowski JQ. Robinson JL, et al. Brain. 2018 Jul 1;141(7):2181-2193. doi: 10.1093/brain/awy146. Brain. 2018. PMID: 29878075 Free PMC article. - Frontotemporal lobar degeneration and dementia with Lewy bodies: clinicopathological issues associated with antemortem diagnosis.
Yokota O. Yokota O. Psychogeriatrics. 2009 Jun;9(2):91-102. doi: 10.1111/j.1479-8301.2009.00286.x. Psychogeriatrics. 2009. PMID: 19604332 Review. - Possible concurrence of TDP-43, tau and other proteins in amyotrophic lateral sclerosis/frontotemporal lobar degeneration.
Takeda T. Takeda T. Neuropathology. 2018 Feb;38(1):72-81. doi: 10.1111/neup.12428. Epub 2017 Sep 27. Neuropathology. 2018. PMID: 28960544 Review.
Cited by
- Targeting Progranulin as an Immuno-Neurology Therapeutic Approach.
Boylan MA, Pincetic A, Romano G, Tatton N, Kenkare-Mitra S, Rosenthal A. Boylan MA, et al. Int J Mol Sci. 2023 Nov 3;24(21):15946. doi: 10.3390/ijms242115946. Int J Mol Sci. 2023. PMID: 37958929 Free PMC article. Review. - TARDBP mutation analysis in TDP-43 proteinopathies and deciphering the toxicity of mutant TDP-43.
Gendron TF, Rademakers R, Petrucelli L. Gendron TF, et al. J Alzheimers Dis. 2013;33 Suppl 1(Suppl 1):S35-45. doi: 10.3233/JAD-2012-129036. J Alzheimers Dis. 2013. PMID: 22751173 Free PMC article. Review. - TARDBP mutations in Parkinson's disease.
Rayaprolu S, Fujioka S, Traynor S, Soto-Ortolaza AI, Petrucelli L, Dickson DW, Rademakers R, Boylan KB, Graff-Radford NR, Uitti RJ, Wszolek ZK, Ross OA. Rayaprolu S, et al. Parkinsonism Relat Disord. 2013 Mar;19(3):312-5. doi: 10.1016/j.parkreldis.2012.11.003. Epub 2012 Dec 8. Parkinsonism Relat Disord. 2013. PMID: 23231971 Free PMC article. - Hippocampal sclerosis, TDP-43, and the duration of the symptoms of dementia of AD patients.
Lopez OL, Kofler J, Chang Y, Berman SB, Becker JT, Sweet RA, Nadkarni N, Patira R, Kamboh MI, Cohen AD, Snitz BE, Kuller LH, Klunk WE. Lopez OL, et al. Ann Clin Transl Neurol. 2020 Sep;7(9):1546-1556. doi: 10.1002/acn3.51135. Epub 2020 Jul 31. Ann Clin Transl Neurol. 2020. PMID: 32735084 Free PMC article. - The Role of TDP-43 in Alzheimer's Disease.
Chang XL, Tan MS, Tan L, Yu JT. Chang XL, et al. Mol Neurobiol. 2016 Jul;53(5):3349-3359. doi: 10.1007/s12035-015-9264-5. Epub 2015 Jun 17. Mol Neurobiol. 2016. PMID: 26081142 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical